Company
Rouge
RougeTx - Developing first-in-class small molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction
- Business model
- B2B
Claim, correct or request removal
Record updated 4 October 2026
About
Developing a small molecule therapy for hereditary hemorrhagic telangiectasia, the second largest genetic bleeding disorder.
Loading relationship preview